nach oben

Journal of Neuro-Oncology

Erschienen in:

01.02.2015 | Laboratory Investigation

MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma

verfasst von: Shoudan Zhang, Qigui Qi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Glioblastomas (GBMs) are the highest grade of primary brain tumors with astrocytic similarity and are characterized dispersal of tumor cell. Metastasis suppressor 1 (MTSS1) play an important role in cancer metastasis. Recent studies indicating that MTSS1 as a potential tumor suppressor and its reduced expression associated with poor prognosis in many cancer types. However, the relationship with the prognosis of patients and the molecular mechanism of MTSS1 renders a tumor suppressor effect in GBM is unknown. Here, we showed that low MTSS1 gene expression is associated with poor outcomes in patients with GBM. Overexpression of MTSS1 in U-87 MG cells exhibited inhibited glioma cell growth, colony formation, migration and invasion. Mechanistically, we found that high MTSS1 expression in U-87 MG reduced expression of CTTN. These results implicate that the role of MTSS1 suppresses cell migration and invasion by inhibiting expression of CTTN and as a prognosis biomarker in GBM.

Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA et al (2014) Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 156(3):603–616PubMedCentralPubMedCrossRef

Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J (2013) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10(1):14–26PubMedCrossRef

Lee YG, Macoska JA, Korenchuk S, Pienta KJ (2002) MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4(4):291–294PubMedCentralPubMedCrossRef

Utikal J, Gratchev A, Muller-Molinet I, Oerther S, Kzhyshkowska J, Arens N et al (2006) The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer 119(10):2287–2293PubMedCrossRef

Parr C, Jiang WG (2009) Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 45(9):1673–1683PubMedCrossRef

Huang XY, Huang ZL, Xu YH, Huang XY, Zhou J, Ye SL et al (2010) Effects of MIM-B gene on invasive and metastatic potentials of human hepatocellular carcinoma MHCC97H cells. Zhonghua Gan Zang Bing Za Zhi 18(12):915–919PubMed

Ma S, Guan XY, Lee TK, Chan KW (2007) Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 38(8):1201–1206PubMedCrossRef

Bompard G, Sharp SJ, Freiss G, Machesky LM (2005) Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci 118(Pt 22):5393–5403PubMedCrossRef

Callahan CA, Ofstad T, Horng L, Wang JK, Zhen HH, Coulombe PA et al (2004) MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev 18(22):2724–2729PubMedCentralPubMedCrossRef

10.

Wang D, Xu MR, Wang T, Li T, Zhu J (2011) MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg 15(7):1205–1212PubMedCrossRef

11.

Weaver AM (2008) Cortactin in tumor invasiveness. Cancer Lett 265(2):157–166PubMedCentralPubMedCrossRef

12.

Lin J, Liu J, Wang Y, Zhu J, Zhou K, Smith N, Zhan X (2005) Differential regulation of cortactin and NWASP- mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene 24(12):2059–2066

13.

Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT (1991) Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 11(10):5113–5124PubMedCentralPubMed

14.

Buday L, Downward J (2007) Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta 1775(2):263–273PubMed

15.

Stuible M, Dube N, Tremblay ML (2008) PTP1B regulates cortactin tyrosine phosphorylation by targeting Tyr446. J Biol Chem 283(23):15740–15746PubMedCentralPubMedCrossRef

16.

MacGrath SM, Koleske AJ (2012) Cortactin in cell migration and cancer at a glance. J Cell Sci 125(Pt 7):1621–1626PubMedCentralPubMedCrossRef

17.

Mezi S, Todi L, Orsi E, Angeloni A, Mancini P (2012) Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells. Int J Oncol 41(6):2128–2138PubMed

18.

Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, Nozawa Y et al (2012) Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol 19(1):71–79PubMedCrossRef

19.

Hirakawa H, Shibata K, Nakayama T (2009) Localization of cortactin is associated with colorectal cancer development. Int J Oncol 35(6):1271–1276PubMedCrossRef

20.

Hashimoto A, Hashimoto S, Ando R, Noda K, Ogawa E, Kotani H et al (2011) GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS ONE 6(8):e23359PubMedCentralPubMedCrossRef

21.

Cen G, Ding HH, Liu B, Wu WD (2014) FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration. Tumour Biol 35(9):8633–82014PubMedCrossRef

22.

Xu XZ, Garcia MV, Li TY, Khor LY, Gajapathy RS, Spittle C et al (2010) Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol 23(2):187–196PubMedCentralPubMedCrossRef

23.

Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X et al (2012) MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene 31(18):2298–2308PubMedCrossRef

24.

Gurtan AM, Sharp PA (2013) The role of miRNAs in regulating gene expression networks. J Mol Biol 425(19):3582–3600PubMedCentralPubMedCrossRef

25.

Li J, Lu X (2013) The emerging roles of 3′ untranslated regions in cancer. Cancer Lett 337(1):22–25PubMedCrossRef

Titel: MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma
verfasst von: Shoudan Zhang
Qigui Qi
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1656-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children’s Cancer Group high-grade glioma study CCG-945

White matter changes in breast cancer brain metastases patients who undergo radiosurgery alone compared to whole brain radiation therapy plus radiosurgery

Primary tumors of the spine: a review of clinical features in 438 patients

Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1

A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres

Treatment strategies and long-term outcomes for primary intramedullary spinal germinomas: an institutional experience